Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | HPGD | P15428 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8930765 | 0.87 | HSP90AA1 (0.58) | ALDH1A1HPGDKDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL931474 | 0.81 | CYP17A1 (0.44) | ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL14293443 | 0.74 | HSP90AA1 (0.59) | ALDH1A1HPGDKDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL8930974 | 0.74 | MAPT (0.65) | ALDH1A1HPGDKDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL8930630 | 0.72 | HSP90AA1 (0.59) | ALDH1A1HPGDKDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL8930993 | 0.72 | HSP90AA1 (0.59) | ALDH1A1HPGDKDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL13983487 | 0.72 | HSP90AA1 (0.52) | ALDH1A1HPGDKDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL14344996 | 0.71 | ALDH1A1 (0.62) | ALDH1A1HPGDKDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL13572218 | 0.71 | CYP17A1 (0.33) | HPGDKDM4EMAPTCYP17A1 | |
| SCHEMBL13983482 | 0.70 | GAA (0.66) | ALDH1A1HPGDKDM4EHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | SYNTA PHARMACEUTICALS CORP (US) | 2015-04-02 | — | — | US | disclosed |
| US-8969396-B2 | Method for treating a B-raf associated cancer with an Hsp90 inhibitor | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140363830-A1 | COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME | SYNTA PHARMACEUTICALS CORP. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8901308-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140221375-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8648104-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648104-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20100273846-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2010-10-28 | — | — | US | disclosed |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP | 2010-04-15 | — | — | US | disclosed |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP | 2010-04-15 | — | — | US | disclosed |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 246/4885HPGD 561/4885KDM4E 2835/4885 |
| US-20140221375-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 743/4885HPGD 2571/4885KDM4E 3577/4885 |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | HSP90AB1, HSP90AB2P, HSP90AA1 | ALDH1A1 1385/4885HPGD 2124/4885KDM4E 2879/4885 |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 2496/4885HPGD 202/4885KDM4E 3814/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | ALDH1A1 1036/4885HPGD 210/4885KDM4E 2790/4885 |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 2514/4885HPGD 498/4885KDM4E 4422/4885 |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | HSP90AB1, HSP90B1, CDC37 | ALDH1A1 2231/4885HPGD 534/4885KDM4E 3500/4885 |
| US-20100273846-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 743/4885HPGD 2571/4885KDM4E 3577/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | ALDH1A1 1385/4885HPGD 2124/4885KDM4E 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.